Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19
NCT ID: NCT04358068
Last Updated: 2021-11-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
20 participants
INTERVENTIONAL
2020-05-13
2020-07-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants were randomized 1:1 to receive active or placebo study treatment. The target sample size was 2000 participants, with approximately 1000 in each arm. Stratification was by "high" versus "low" risk of progression to severe COVID-19, where "high risk" was defined as a person age ≥60 years or having at least one of several specified comorbidities.
Participants were prescribed study treatment for 7 days and were to be followed for an additional 24 weeks. Assessments on a subset of participants were planned to include blood collection, self-collected nasal swabs, and nasopharyngeal swabs.
On June 23, 2020, sites were informed that the study was closing to follow-up due to slow enrollment and lack of community enthusiasm. Follow-up through week 24 was not completed for any participant. Participants were asked to complete the Day 20 visit and then were discontinued from the study. Due to the early termination, enrollment into the specimen collection subset did not occur, and results associated with those specimens are not available. Due to the small number of participants enrolled, some statistical tests were not able to be performed and only descriptive results are provided.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)
Hydroxychloroquine 400 mg (administered as two 200 mg capsules) orally twice daily for 2 doses starting on Day 0, followed by 200 mg (administered as one 200 mg capsule) orally twice daily for 12 doses (6 days), PLUS:
Azithromycin 500 mg (administered as two 250 mg capsules) orally as a single dose on Day 0, followed by 250 mg (administered as one 250 mg capsule) orally once daily for 4 doses (4 days).
Hydroxychloroquine (HCQ)
Administered orally
Azithromycin (Azithro)
Administered orally
Arm B: Placebo for Hydroxychloroquine and Azithromycin
Placebo for Hydroxychloroquine (administered as two matching placebo capsules) orally twice daily for 2 doses starting on Day 0, followed by Placebo for HCQ (administered as one 200 mg capsule) orally twice daily for 12 doses (6 days), PLUS:
Placebo for Azithromycin (administered as two matching placebo capsules) orally as a single dose on Day 0, followed by Placebo for Azithromycin (administered as one matching placebo capsule) orally once daily for 4 doses (4 days).
Placebo for Hydroxychloroquine
Administered orally
Placebo for Azithromycin
Administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hydroxychloroquine (HCQ)
Administered orally
Azithromycin (Azithro)
Administered orally
Placebo for Hydroxychloroquine
Administered orally
Placebo for Azithromycin
Administered orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Experienced at least one of the following SARS-CoV-2 infection symptoms within 24 hours of screening (symptom(s) must be new or worse compared to pre-COVID-19 health status):
* Fever (can be subjective) or feeling feverish
* Cough
* Shortness of breath or difficulty breathing at rest or with exertion
* Sore throat
* Body pain or muscle pain
* Fatigue
* Headache
* Agreed to not participate in another clinical trial for the treatment of COVID-19 or SARS-CoV-2 during the study period up until reaching hospitalization or 20 days, whichever is earliest.
* Agreed to not obtain study medications outside of the A5395 study.
Exclusion Criteria
* History of or current hospitalization for COVID-19.
* History of ventricular arrhythmia or use of antiarrhythmics within 30 days prior to entry.
* Personal or family history of Long QT syndrome.
* History of kidney disease.
* History of ischemic or structural heart disease.
* History of hypokalemia or hypomagnesemia or taking potassium supplementation or magnesium supplementation
* Personal medical history of porphyria, retinopathy, severe hepatic impairment, or glucose-6-phosphate dehydrogenase (G6PD) deficiency.
* Used drugs with possible anti-SARS-CoV-2 activity within 30 days prior to study entry, e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, and azithromycin, or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis.
* Requirement or expected requirement for a medication that significantly prolongs QT intervals or increases risk for QT prolongation.
* Loop diuretics are exceptions to above exclusion criterion but these cannot be used within 30 days prior to study entry.
* Participated in a study where co-enrollment was not allowed.
* Receipt of a SARS-CoV-2 vaccination prior to study entry.
* Known allergy/sensitivity or any hypersensitivity to components of HCQ, azithromycin, or their formulation.
* More than 10 days of any of the following symptoms attributed to the SARS-CoV-2 infection at study entry:
* Fever (can be subjective) or feeling feverish
* Cough
* Shortness of breath or difficulty breathing at rest or with exertion
* Sore throat
* Body pain or muscle pain
* Fatigue
* Headache
* Chills
* Nasal obstruction or congestion
* Loss of taste or smell
* Nausea or vomiting
* Diarrhea
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Teva Pharmaceutical Industries, Ltd.
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Davey Smith, MD
Role: STUDY_CHAIR
University of California, San Diego
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alabama CRS
Birmingham, Alabama, United States
UCSD Antiviral Research Center CRS
San Diego, California, United States
Harbor-UCLA CRS
Torrance, California, United States
Whitman-Walker Health CRS
Washington D.C., District of Columbia, United States
Northwestern University CRS
Chicago, Illinois, United States
Rush University CRS
Chicago, Illinois, United States
Greensboro CRS
Greensboro, North Carolina, United States
Cincinnati Clinical Research Site
Cincinnati, Ohio, United States
University of Pittsburgh CRS
Pittsburgh, Pennsylvania, United States
Trinity Health and Wellness Center CRS
Dallas, Texas, United States
University of Washington AIDS CRS
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Document Type: Informed Consent Form
Related Links
Access external resources that provide additional context or updates about the study.
Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (Corrected Version 2.1 - July 2017)
Manual for Expedited Reporting of Adverse Events to DAIDS (DAIDS EAE Manual), Version 2.0, January 2010
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
38720
Identifier Type: OTHER
Identifier Source: secondary_id
ACTG A5395
Identifier Type: -
Identifier Source: org_study_id